A detailed history of Black Rock Inc. transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Black Rock Inc. holds 160,416 shares of ANIX stock, worth $510,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
160,416
Previous 154,662 3.72%
Holding current value
$510,122
Previous $482,000 26.56%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.21 - $3.35 $12,716 - $19,275
5,754 Added 3.72%
160,416 $354,000
Q1 2024

May 10, 2024

SELL
$3.08 - $5.02 $6,575 - $10,717
-2,135 Reduced 1.36%
154,662 $482,000
Q4 2023

Feb 13, 2024

SELL
$2.85 - $4.19 $13,591 - $19,982
-4,769 Reduced 2.95%
156,797 $608,000
Q3 2023

Nov 13, 2023

SELL
$2.97 - $3.87 $267,311 - $348,315
-90,004 Reduced 35.78%
161,566 $528,000
Q2 2023

Aug 11, 2023

BUY
$3.0 - $5.97 $12,630 - $25,133
4,210 Added 1.7%
251,570 $805,000
Q1 2023

May 12, 2023

SELL
$3.86 - $5.0 $180,875 - $234,295
-46,859 Reduced 15.93%
247,360 $1.06 Million
Q4 2022

Feb 13, 2023

SELL
$3.78 - $5.81 $12,451 - $19,138
-3,294 Reduced 1.11%
294,219 $1.25 Million
Q3 2022

Nov 14, 2022

BUY
$2.81 - $6.15 $549,644 - $1.2 Million
195,603 Added 191.94%
297,513 $1.46 Million
Q2 2022

Aug 12, 2022

SELL
$2.55 - $4.1 $137 - $221
-54 Reduced 0.05%
101,910 $311,000
Q1 2022

May 12, 2022

SELL
$2.5 - $3.42 $8,010 - $10,957
-3,204 Reduced 3.05%
101,964 $279,000
Q4 2021

Feb 10, 2022

SELL
$2.88 - $5.5 $14,757 - $28,182
-5,124 Reduced 4.65%
105,168 $312,000
Q3 2021

Nov 09, 2021

SELL
$3.57 - $5.6 $27,621 - $43,327
-7,737 Reduced 6.56%
110,292 $525,000
Q2 2021

Aug 11, 2021

BUY
$3.46 - $4.92 $408,380 - $580,702
118,029 New
118,029 $458,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $97.5M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.